U.S. Oil and Gas Stock News

Mitek Systems (MITK) opened Q1 2026 with total revenue of US$44.2 million and basic EPS of US$0.06, setting a clear marker for how the year is starting to shape up after a period of sharp reported earnings growth over the past 12 months. The company has seen trailing twelve month revenue move from US$172.1 million in Q4 2024 to US$186.7 million in Q1 2026, with trailing EPS over the same window rising from US$0.07 to US$0.35, putting more weight behind the recent improvement in profitability...

Lexicon Pharmaceuticals (LXRX) just closed FY 2025 with fourth quarter revenue of US$5.5 million and a basic EPS loss of US$0.04, alongside net income losses of US$15.5 million, keeping the focus squarely on how quickly the top line can scale against persistent red ink. The company has seen quarterly revenue move from US$26.6 million in Q4 2024 to US$5.5 million in Q4 2025, with EPS shifting from a loss of US$0.09 to a loss of US$0.04 over the same periods. Trailing 12 month revenue stands at...

ZipRecruiter (ZIP) just posted its FY 2025 numbers with Q4 revenue of US$111.7 million and a basic EPS loss of US$0.01, while the trailing 12 month figures show revenue of US$449.0 million and a basic EPS loss of US$0.37. The company has seen recent quarterly revenue range between US$110.1 million and US$115.0 million, with basic EPS losses stretching from US$0.13 in Q1 2025 to US$0.01 in Q4 2025. This has kept the trailing year firmly in loss making territory even as forecasts point to...

Natera FY 2025 earnings snapshot Natera (NTRA) closed FY 2025 with fourth quarter revenue of US$665.5 million and basic EPS of US$0.34, as net income excluding extra items came in at US$47.3 million. The company has seen revenue move from US$476.1 million in Q4 2024 to US$665.5 million in Q4 2025, while trailing twelve month basic EPS over the same period went from a US$1.53 loss to a US$1.52 loss. This points to a story where top line scale is starting to show through in the margin...

If you are wondering whether Boise Cascade’s current share price offers good value, the recent share performance gives a useful starting point but not the full story. The stock last closed at US$72.76, with a 7 day return of 8.2% decline, a 30 day return of 2.6% decline, a year to date return of 1.8% decline, and a 1 year return of 17.9% decline, set against 3 year and 5 year returns of 14.9% and 35.5% respectively. Recent coverage has focused on Boise Cascade as part of evergreen analysis...

Expensify (EXFY) just closed FY 2025 with fourth quarter revenue of US$35.2 million, a basic EPS loss of US$0.08 per share, and a quarterly net loss of US$7.1 million. On a trailing 12 month basis, the company recorded revenue of US$142.1 million and a net loss of US$21.4 million. Over recent quarters, revenue has moved in a tight band between US$35.1 million and US$37.0 million, while quarterly basic EPS has ranged from a loss of US$0.02 to US$0.10 per share. This has left investors focused...

CareTrust REIT (CTRE) has wrapped up FY 2025 with fourth quarter revenue of US$134.9 million and basic EPS of US$0.50, setting the tone for a year where trailing twelve month revenue reached US$476.4 million and EPS came in at US$1.57. Over the past six reported quarters, revenue has moved from US$77.4 million in Q3 2024 to US$134.9 million in Q4 2025, while quarterly basic EPS has ranged from US$0.21 to US$0.50. This leaves investors focused on how these headline figures line up with the...

Alta Equipment Group (ALTG) has just posted another loss-making quarter, with Q4 FY 2025 revenue of US$509.1 million and basic EPS of a US$0.39 loss, while trailing twelve month revenue sits at US$1.84 billion and EPS at a US$2.55 loss. Over the past six reported quarters, revenue has moved within a range of US$422.6 million to US$509.1 million per quarter as losses have fluctuated between US$0.21 and US$1.31 per share, underscoring a business that is still working through margin pressure...

10x Genomics (TXG) closed out FY 2025 with Q4 revenue of US$166.0 million and a basic EPS loss of US$0.13, alongside trailing twelve month revenue of US$642.8 million and a TTM basic EPS loss of US$0.35. Over recent quarters, the company has seen revenue fluctuate between US$149.0 million and US$172.9 million, while quarterly basic EPS has moved between a loss of US$0.40 and a profit of US$0.28, highlighting an uneven path on the income line. For investors, the latest print keeps the focus on...

Arrowhead Pharmaceuticals (ARWR) opened 2026 with Q1 revenue of US$264.0 million and basic EPS of US$0.22, while trailing twelve month figures show revenue of US$1.1 billion and basic EPS of US$1.48 as the company stayed in profitable territory over the last year. Over recent quarters, revenue has moved from US$2.5 million in Q1 2025 to US$542.7 million in Q2 2025 and US$256.5 million in Q4 2025, with EPS shifting from a loss of US$1.39 per share in Q1 2025 to a profit of US$2.78 per share in...

Inseego (INSG) has wrapped up FY 2025 with fourth quarter revenue of US$48.4 million and a basic EPS loss of US$0.03, alongside net income from continuing operations of a US$0.46 million loss. Over recent quarters, the company has seen revenue move from US$31.7 million in Q1 2025 to US$45.9 million in Q3 2025 and then US$48.4 million in Q4 2025. Quarterly EPS shifted between a loss of US$0.14 in Q1 2025, a profit of US$0.03 in Q3 2025, and back to a small loss in Q4 2025. This sets up a story...

Tucows (TCX) has just wrapped up FY 2025 with Q4 revenue of about US$98.7 million and a basic EPS loss of US$1.98, alongside a Q4 net loss of US$22.0 million. Over the past six quarters, revenue has moved from US$92.3 million in Q3 2024 to US$98.7 million in Q4 2025. Quarterly basic EPS has ranged from a loss of US$3.86 in Q4 2024 to a loss of US$1.98 in the latest quarter. Trailing twelve month EPS currently sits at a loss of US$6.85 on revenue of US$390.3 million as margins remain under...

Q1 2026 earnings snapshot Natural Grocers by Vitamin Cottage (NGVC) opened fiscal 2026 with Q1 revenue of US$335.6 million and basic EPS of US$0.49, setting the tone for its latest earnings update. The company reported revenue of US$330.2 million and EPS of US$0.43 in Q1 2025, compared with US$335.6 million and EPS of US$0.49 in Q1 2026. Trailing twelve month EPS stands at US$2.08 on revenue of about US$1.3 billion, with higher net profit margins and earnings growth framing the quarter as one...

E.W. Scripps (SSP) just reported FY 2025 fourth quarter results with revenue of US$560.3 million and basic EPS of US$0.51 loss, set against a year earlier fourth quarter that showed revenue of US$728.4 million and basic EPS of US$0.93. Over recent periods the company has seen quarterly revenue move from US$646.3 million and EPS of US$0.37 in 2024 Q3 to US$560.3 million and EPS of US$0.51 loss in 2025 Q4. Trailing 12 month revenue sits at about US$2.2 billion with basic EPS of US$1.87 loss...

Cerence (CRNC) opened Q1 2026 with total revenue of US$115.1 million, Basic EPS of a US$0.12 loss, and net income excluding extra items of a US$5.2 million loss, while the trailing 12 months show Basic EPS of roughly US$0.01 and net income excluding extra items of about US$0.3 million. Over recent quarters the company has seen revenue move from US$50.9 million in Q1 2025 to US$115.1 million in Q1 2026, alongside Basic EPS shifting from a US$0.57 loss to a US$0.12 loss and trailing 12 month...

If you are wondering whether Sarepta Therapeutics at US$20.80 is starting to look like value or still carries too much risk, the recent share price and fundamentals give you a lot to weigh up. The stock has been under pressure, with returns of 0.4% decline over 7 days, 9.9% decline over 30 days, 2.4% decline year to date, 43.0% decline over 1 year and 82.7% decline over 3 years, while the 5 year return sits at 71.3% decline. Recent news around Sarepta Therapeutics has focused on its position...

National Health Investors (NYSE:NHI) is selling its entire skilled nursing facility portfolio for $560 million. The company plans to redeploy proceeds into private-pay senior housing, including a seven-property portfolio in Colorado. This shift reduces exposure to skilled nursing and increases focus on private-pay assets that management views as offering more attractive risk adjusted returns. For investors watching NYSE:NHI, this move comes with the stock recently closing at $75.07 and...

Pacific Biosciences of California (PACB) has just posted its FY 2025 numbers, with Q4 revenue at US$44.6 million and a basic EPS loss of US$0.13 set against trailing twelve month revenue of US$160.0 million and a TTM basic EPS loss of US$1.82. Over the past six reported quarters, the company has seen quarterly revenue move between US$37.2 million and US$44.6 million, while basic EPS has ranged from a small profit of US$0.01 in FY 2024 Q4 to a loss of US$1.44 in FY 2025 Q1. This leaves...

Genius Sports (GENI) opened Q1 2026 with revenue of US$188 million, a basic EPS loss of US$0.21 per share, and net income loss of US$55 million, setting a cautious tone around near term profitability. The company has seen quarterly revenue move from US$144 million in Q1 2025 to US$188 million in Q1 2026, while basic EPS shifted from a loss of US$0.03 to a loss of US$0.21 over the same period. This puts the focus squarely on how efficiently that extra revenue is translating into results. For...

ACADIA Pharmaceuticals (ACAD) opened 2026 with Q1 revenue of $268.1 million and basic EPS of $0.02, against a backdrop of trailing twelve month revenue of $1.1 billion, basic EPS of $2.22 and net income of $375.7 million. Over recent quarters, the company has seen revenue move from $244.3 million in Q1 2025 to $268.1 million in Q1 2026, while quarterly basic EPS has ranged from $0.11 to $1.62. These results come within a period of margin expansion and earnings growth that investors now need...

If you are wondering whether Ouster's share price still offers value after a strong run, it helps to start by lining up the recent returns with what the current valuation really implies. Ouster's stock closed at US$24.51, with returns of 26.8% over 30 days, 4.9% year to date and 183.4% over 1 year, while the last 7 days show a 9.1% decline and the 5 year figure sits at a 70.9% loss. Taken together, these figures suggest investors have been reassessing both potential and risk over different...

This article considers whether Coinbase Global's recent share price suggests a potential bargain or already reflects its current story, by comparing its value against several common yardsticks. At a last close of US$192.96, the stock has returned 2.8% over the past week and 10.1% over the past month. It is down 18.4% year to date and has returned 219.7% over three years and 27.2% over five years. Recent headlines around Coinbase Global have focused on its role as a listed gateway to crypto...

Warner Music Group and Paramount Pictures have agreed a multi year, first look partnership to develop theatrical films based on Warner Music artists and songwriters. The deal focuses on creating new cinema projects that tap into both legendary and contemporary acts from Warner Music Group. This collaboration pairs a major recorded music company with a leading Hollywood studio to build film concepts around music IP. For investors watching NasdaqGS:WMG, this new film partnership sits...

If you are wondering whether Regeneron Pharmaceuticals at around US$709.10 is priced attractively or already reflects the story, the valuation picture is where the answers start to emerge. The stock is up 0.3% over the last 7 days, while it shows a 6.7% decline over 30 days, an 8.7% decline year to date, and a 30.2% return over the past year, which can change how investors think about both upside potential and risk. Recent headlines around Regeneron often focus on its position within large...